Subscribe

Garrison Film Productions Inc. (EMDF)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Medical - Specialties
Address 4054 Sawyer Road 34233
Sarasota, FL, US
CEO Gary Kompothecras
IPO 2003-04-22
CIK 894552 ISIN US26875D1081

Explore sections of this company profile

Description

Garrison Film Productions Inc. engages in the investment, financing, and production of films. The company was formerly known as E Med Future, Inc. and changed its name to Garrison Film Productions Inc. in April 2023. The company is based in Sarasota, Florida.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10.8K
Beta
-0.84
Float Shares
42.54M
Free Float %
99.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% -2.44% -2.44% +17.65% -27.27% +21.21% -20.00% -80.00% -96.20% +185.71% -99.85%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.05
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Specialties: +8.3%
    +49.9% Q3'08: +19,092.5% (vs Q3'07)
  • EPS growth Medical - Specialties: +10.1%
    +0.0% Q3'08: +38.9% (vs Q3'07)
  • FCF margin FCF growth · Medical - Specialties: +51.3%
    +14.8% Q3'08: -1,764.4% (vs Q3'07)
  • EBIT margin Medical - Specialties: +12.6%
    -133.6% Q3'08: -113.5% (vs Q3'07)
  • ROIC Medical - Specialties: +6.6%
    Q3'08: -1.2% (vs Q3'07)
  • Share dilution Medical - Specialties: 0.0%
    +15.2% Q3'08: +0.0% (vs Q3'07)
  • Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    -4.56× Q3'08: -61.59× (vs Q3'07)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.83) × ERP
WACC = 0% × Ke + 0% × Kd (0.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-71.0K
OE per share TTM
0.00
Owner's Yield
-41.75%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
46.4%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1
Total invested
10.00
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
# Reporting person Amount owned % of class Sole voting Shared voting Sole dispositive Shared dispositive Type Citizenship Filing date SEC filing
1 D. Dane Donohue 3.50M 10.30% 10.00 10.00 10.00 10.00 IN America 2005-02-01
2 Robert J. Ochsendorf 3.00M 8.80% 10.00 10.00 10.00 10.00 IN America 2005-02-01
3 Juan J. Perez 1.38M 4.00% 250.0K 250.0K 250.0K 250.0K IN America 2005-02-01

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2025 Q4
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
Puts held
Top institutional holders
# Investor Shares / Δ Mkt value / Δ Own% / Δ Weight% / Δ Avg px / Perf. Hold / Status
1 ANCORA ADVISORS, LLC -3.0K (-100.0%) -10.0 (-100.0%) 0.00% -0.007 pp 0.00% +0.000 pp USD 13 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
42.56M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2011-12-23 DEF 14A
2011-12-16 PRE 14A

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2023-08-11 QUALIF
2023-05-16 1-A
2023-01-06 SEC STAFF ACTION
2021-11-05 1-A
2014-09-30 15-15D
2012-12-03 8-K/A
2012-11-06 8-K
2012-10-25 8-K
2012-10-12 UPLOAD
2012-10-05 CORRESP

Executive team

NameTitleCompensationGender
Gary G. Kompothecras Chief Executive Officer, President & Director male
ESG Rating
B+
MEDICAL - DEVICES
2006
E (Environmental)
70.1 / 62.5
Company / Sector avg.
S (Social)
63.0 / 68.9
Company / Sector avg.
G (Governance)
69.9 / 64.8
Company / Sector avg.
ESG Total
67.7 / 65.4
Company / Sector avg.
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits